Key result
Among 85 women who developed a thromboembolic event while on oral contraceptives or hormone replacement therapy, 65 (76.5%) had at least one additional thrombophilia risk factor.
Why the study?
What is the prevalence of thrombophilia in women who develop thromboembolic events while on oral contraceptives or hormone replacement therapy?
Population
85 women who developed a thromboembolic event while on oral contraceptives or hormone replacement therapy…
Design
Case_series
Authors
Loading...
Suggests considering thrombophilia history before OC/HRT; hypothesis-generating and leaves open prospective validation.
Observational (n=85)
What is the prevalence of thrombophilia in women who develop thromboembolic events while on oral contraceptives or hormone replacement therapy?
There is a high prevalence of underlying thrombophilia in women who develop thromboembolic events while using oral contraceptives or HRT, highlighting the importance of evaluating family and personal history of thrombosis prior to initiating therapy.
DeSancho et al. (2010) conducted an observational in Thromboembolic events (n=85). Oral contraceptives or hormone replacement therapy was evaluated on Prevalence of thrombophilia. Among 85 women who developed a thromboembolic event while on oral contraceptives or hormone replacement therapy, 65 (76.5%) had at least one additional thrombophilia risk factor.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: